February 6, 2026 | Vensana Capital® Portfolio News

SpyGlass Pharma Announces Pricing of Initial Public Offering

22

Novel FDA PMA & de novo 510k approvals

61

U.S. Commercial Product Launches

40

Level I Clinical Trials

34

Strategic Financings

32

Exits by IPO or M&A